mammaprint dna microarray-based test for prognosis of her2þ early breast cancers (Agendia BV)
90
Structured Review
Agendia BV
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mammaprint dna microarray-based test for prognosis of her2þ early breast cancers/product/Agendia BV
Average 90 stars, based on 1 article reviews
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mammaprint dna microarray-based test for prognosis of her2þ early breast cancers/product/Agendia BV
Average 90 stars, based on 1 article reviews
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers - by Bioz Stars,
2026-04
90/100 stars